ArticleTranslational lung cancer research2026
Exploratory study to evaluate the combined effect of CBM588:
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Platinum plus pemetrexed and pembrolizumab is a standard first-line treatment for advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) without actionable driver alterations, including tumors with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) <50%. However, the clinical benefits vary, and biomarkers for this chemoimmunotherapy regimen remain limited. CBM588, a live biotherapeutic preparation containing Methods: This is a multi-institutional, single-arm, phase II exploratory study enrolling 20 treatment-naïve patients with advanced or recurrent non-squamous NSCLC and a PD-L1 TPS <50%. Patients will receive continuous CBM588 from the start of the protocol treatment in combination with platinum, pemetrexed, and pembrolizumab. After four induction cycles, maintenance pemetrexed plus pembrolizumab will be continued until disease progression or unacceptable toxicity. The primary endpoints are response rate and progression-free survival (PFS). Tumor response will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Stool samples will be collected before treatment, cycle 3, and cycle 5 for 16S rRNA sequencing to evaluate microbial diversity and responder-associated taxa. Discussion: This trial will prospectively assess CBM588 added to platinum plus pemetrexed and pembrolizumab in NSCLC with PD-L1 TPS <50% while monitoring the gut microbiota. These findings may inform microbiota-targeted strategies for optimizing chemoimmunotherapy. Trial Registration: This study was registered in the Japan Registry of Clinical Trials (No. jRCT1071260004) on 6 April 2026.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.